Transarterial chemoembolisation using small diameter drug eluting beads in patients with neuroendocrine tumour liver metastasis

Congress:

ECR 2018

Poster Number:

C-0190

Type:

Scientific Exhibit

Keywords:

Interventional vascular, Liver, Catheter arteriography, Fluoroscopy, Chemoembolisation, Cancer, Endocrine disorders

Authors:

K. Mahmoud, H. El Khudari, S. Moawad, S. Saddekni, N. Ertel, R. Oser, N. A. Aboueldahab, B. Hamed, A. M. K. Abdel Aal; Birmingham, AL/US

DOI:

10.1594/ecr2018/C-0190

DOI-Link:

https://dx.doi.org/10.1594/ecr2018/C-0190

Fig. 1: The chart shows percentage of tumor response after transarterial...

Table 1: Patients Demographic and Tumor characteristics.

Table 2: Clinical symptoms improvement after transarterial chemoembolization for...

Table 3: Overall survival after transarterial chemoembolization for neuroendocrine tumor...

Aims and objectives

The aim of this study is to evaluate tumor response, symptom relief, survival outcomes and toxicity of transarterial chemoembolization using small size drug eluting beads (DEB-TACE) in the treatment of patients with liver metastasis from neuroendocrine tumors (NET).

Methods and materials

We retrospectively reviewed the medical records and radiologic studies of 17 patients with liver-dominant metastatic NET between June 2013 and April 2017 who underwent DEB-TACE using 75 µm Oncozene (Boston Scientific)DEB. Patients who had lesions previously treated with TACE or other loco-regional therapy were excluded. Imaging follow up was done 4-6 weeks after TACE. Tumor response was measured by m-RECIST criteria. Clinical follow up and change in symptoms and signs were obtained from the patients' medical charts. Toxicity was assessed according to Common Terminology Criteria...

Results

The study included 9 males (53%) and 8 females (47%) with a mean age of 64.6 (SD=11.5) years. Most of the primary tumors were from gastrointestinal tract in 11 patients (64.7%), pancreas in 2 patients (11.8%), lungs in 2 patients (11.8%), ovary in 1 patient (5.9%) and unknown in 1 patient (5.9%). Tumor burden ≥50% was seen in 5 patients (29.4%) (Fig. 1). Imaging follow-up was available for 14 out of 17 patients (82.3%). Complete response was seen in 3 patients (21.4%), partial response was...

Conclusion

TACE using small size DEB is highly effective in controlling symptoms in patients with NET liver metastasis with very low toxicity profile and better radiologic response compared to published literature.

Personal information

Ahmed KamelAbdel Aal , MD,PhD, FSIR University of Alabama at Birmingham (UAB). Department of Radiology Division ofInterventional Radiology. United States , Alabama. Address: 619 19th Street South, Birmingham, AL 35249. Tel:(205) 975-4850 Fax: (205) 975-5257. Email: [email protected] Twitter: ahmed_kamel_ir

References

Pericleous M. Asian Pac J Vlin Oncol. 2016 March. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes. Bhagat N. Cardiovasc Intervent Radiol. 2013 Apr. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Kennedy A. HPB (Oxford). 2015 Jan. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.